Because miRNA-34a is encoded as an NF-kB-sensitive transcript, anti-NF-kB and/or anti-miRNA strategies and/or combinatorial approaches, perhaps with other targeted anti-inflammatory therapies, may be useful in the clinical management of AMD and in other disorders of the CNS with an amyloidogenic component [79–85]. Here, NFKB1 is linked to age-related macular degeneration.